Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Harrow

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
From Harrow
Via Business Wire
Tickers HROW
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Harrow
Via Business Wire
Tickers HROW
Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.
From Harrow
Via Business Wire
Tickers HROW
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
From Harrow
Via Business Wire
Tickers HROW
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
From Harrow
Via Business Wire
Tickers HROW
Harrow Launches Next-Generation Compounded Atropine Formulations
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
From Harrow
Via Business Wire
Tickers HROW
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
From Harrow
Via Business Wire
Tickers HROW
Harrow Prices $25 Million Offering
From Harrow
Via Business Wire
Tickers HROW
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
From Harrow
Via Business Wire
Tickers HROW
Harrow and iOR Partners Expand National Product Supply Agreement
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces Third Quarter 2022 Financial Results
From Harrow
Via Business Wire
Tickers HROW
Harrow Launches Atropine.com
From Harrow
Via Business Wire
Tickers HROW
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
From Harrow
Via Business Wire
Tickers HROW
Harrow Sells Non-Ophthalmic Compounding Business
From Harrow
Via Business Wire
Tickers HROW
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
From Harrow
Via Business Wire
Tickers HROW
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
From Harrow
Via Business Wire
Tickers HROW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.